Showing results (111-120 of 118) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.Cell|January 20, 2022
Magnesium sensing via LFA-1 regulates CD8+ T cell effector functionJonas Lötscher, Adrià-Arnau Martí I Líndez, Nicole Kirchhammer, et al.Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR TrialSolange Peters, Sarah Danson, Baktiar Hasan, et al.JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.Pageof 12